A new study has found that a combination of two drugs could enhance the immune system to treat one of the most common types of cancer in the world, bowel cancer. Also known as colorectal cancer, despite its widespread presence, the treatment options for this condition are limited. What the study specifically found was that this procedure could shrink the tumours caused by this condition by around 60%.

What Are The Drugs Involved

The trial involved the use of two immunotherapy drugs, botancilimab and balstilumab. It is a monoclonal antibody that works to stimulate the body's immune system to attack cancer. The study is a rather significant find, as it’s the first time that a consistent and durable response to immunotherapy has been reported in patients with solid MSS mCRC tumours.

The study was divided into several phases for more than 6 months. In the US trial, around around 101 patients with microsatile stable metastatic colorectal (MSS-mCRC) tumours showed a decrease . Around 61% of the patients experienced tumour shrinkage or stabilization after combined treatment with votancilumab and balstilumab. When it comes to downsides, diarrhea and fatigue were found to be the most common side effects or side effects of this drug.

These results are interesting and open to exploration. To date, immunotherapy has not been effective in patients with CNS-mCRC tumors. This study demonstrates the potential of the combination of botenlimab and balstilimab in the treatment of CNS mCRC, providing new hope for people diagnosed with colon cancer.

What Could This Mean For Bowel Cancer Treatment In The Future

The study is currently in the final stages of clinical trials, and the US Food and Drug Administration (FDA) hopes to quickly gain approval for its use because of the importance of this area that affects many people. The efficiency shown demonstrates the potential of botansilimab to contribute to broad antitumor immunity.

All in all, the combination of botensilimab and balstilimab represents a promising new direction in the treatment of colorectal cancer. This breakthrough could improve conditions for many patients worldwide and lights a new hope in the fight against this common disease. The results of this study show the effectiveness of immunotherapy in this field and how its potential to transform cancer treatment can only grow in the years to come.

US Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. has announced food policy reforms as part of efforts to implement President Donald Trump’s Make America Healthy Again (MAHA) initiative.

The proposed measures focus on two areas: greater oversight of food ingredients and establishing a standardized federal definition of ultra-processed foods.

As per Kennedy, “nearly 60% of the American diet is made up of ultra-processed foods, and childhood obesity now affects more than one in five American children”.

To counter this, transforming the food system is key, he said.

“These historic actions bring greater transparency to what’s in our food and stronger science to federal nutrition policy. President Trump and I promised to Make America Healthy Again, and today we are turning that promise into policy,” Kennedy said.

What Are the Proposed Changes?

HHS has proposed a rule that would require manufacturers to notify the US Food and Drug Administration (FDA) when they determine that a substance added to human or animal food is Generally Recognized as Safe (GRAS).

In addition, HHS and the US Department of Agriculture (USDA) have submitted for final review the federal government’s first proposed definition of ultra-processed foods (UPFs).

Acting FDA Commissioner Kyle Diamantas said the measures are intended to increase transparency and strengthen science-based oversight of ingredients entering the food supply.

“By proposing mandatory GRAS notifications, we are closing critical information gaps and giving the FDA greater visibility into substances entering the food supply,” Diamantas said.

He added that the proposed UPF definition could provide a stronger foundation for future nutrition research.

What Is GRAS?

GRAS stands for Generally Recognized as Safe. It refers to substances that are considered safe by qualified experts for their intended use and are therefore exempt from the standard premarket approval requirements for food additives.

Examples of GRAS ingredients include canola oil, vinegar and spices such as black pepper.

Under the proposed rule, manufacturers would be required to notify the FDA when they conclude that a substance qualifies as GRAS. The agency would also expand its public-facing inventory of submitted GRAS notices.

According to Diamantas, mandatory notifications would help close information gaps and give the FDA greater visibility into substances entering the food supply.

First Federal Definition of Ultra-Processed Foods

HHS and USDA have submitted for final review the federal government’s first proposed definition of ultra-processed foods.

Research has linked high consumption of UPFs with preventable chronic diseases, including type 2 diabetes and heart disease. However, the absence of a standardized federal definition has made it difficult to maintain consistency in research across federal agencies.

The proposed definition incorporates feedback from thousands of stakeholders, including industry representatives, consumer organizations, researchers and members of the public.

Diamantas said the definition could help “create a stronger foundation for future nutrition research.”

How Does This Support Trump’s MAHA Agenda?

The measures are part of the Trump administration’s Make America Healthy Again Strategy and build on efforts to strengthen nutrition science, improve transparency and modernize oversight of the US food supply.

HHS also encouraged Congress to build on these efforts through legislation aimed at further strengthening the safety of the American food supply.

The death toll from Ebola has crossed 2,000 in the Democratic Republic of the Congo (DRC), three months after the outbreak was officially declared in May.

The outbreak has caused 4,381 confirmed cases across five provinces, making it the fastest-growing Ebola outbreak recorded in the Central African country. The response has been complicated by strikes by unpaid health workers, misinformation and cultural practices.

Ebola Virus Outbreak Began in February

The outbreak is caused by the rare Bundibugyo strain of Ebola, for which there is currently no approved treatment or vaccine.

According to the World Health Organization (WHO), the virus first emerged in the DRC in February, about three months before the outbreak was officially declared in the DRC and neighboring Uganda on May 15.

Some early patients were reportedly treated for malaria or typhoid, which can initially cause fever, weakness, vomiting and diarrhea. Early testing also focused on the more common Zaire strain of Ebola, delaying recognition of the Bundibugyo virus.

By early May, WHO had identified an unusual cluster of severe illness and deaths in the Mongbwalu health zone in Ituri Province. An investigation covering April 15 to May 13 subsequently identified 246 suspected cases and 65 deaths across three health zones.

The response has also been affected by conditions in Ituri, including armed conflict, population displacement and poor road access. Health workers have faced shortages of protective equipment, while some healthcare facilities have been affected by workers' strikes.

Zoonotic Spillover Likely Triggered the Outbreak

A new study published in Nature Medicine suggests that the outbreak began through a zoonotic spillover event, meaning the virus jumped from animals to humans before spreading between people.

Researchers from Congo, Uganda, Belgium and other countries found that the outbreak strain was genetically distinct from Bundibugyo Ebola viruses identified during previous outbreaks in 2007 and 2012.

The findings are consistent with a new animal-to-human transmission event, followed by sustained human-to-human transmission.

The study did not identify the specific animal source. However, Ebola viruses are known to periodically spill over from infected animals into human populations.

Genetic analysis also confirmed that cases detected in Uganda were linked to the outbreak in Congo.

How Was the Study Conducted?

Bundibugyo virus disease (BVD) outbreaks were previously recorded in 2007–2008 in Bundibugyo District, Uganda, and in 2012 in Isiro, DRC.

For the 2026 outbreak, researchers generated 22 viral genomes from samples collected from patients with BVD in the DRC and Uganda.

The genomes formed a well-supported phylogenetic cluster separate from variants associated with the 2007 and 2012 outbreaks. The analysis also showed evidence of sustained human-to-human transmission.

The researchers called for greater decentralized laboratory diagnostic capacity, including pan-Orthoebolavirus testing and genomic sequencing, to improve early detection and control of future outbreaks.

How Does Ebola Spread From Animals to Humans?

Ebola can jump to humans from infected animals such as bats, monkeys and apes. Transmission can occur through contact with blood, body fluids, excrement or raw meat during hunting and butchering.

Once the virus enters the human population, it can spread from person to person through contact with infected bodily fluids.

Symptoms of Bundibugyo Virus Disease

Symptoms of Bundibugyo virus disease are similar to those caused by other Ebola viruses and can include:

• Fever
• Headache
• Muscle pain
• Weakness
• Diarrhea
• Vomiting
• Stomach pain
• Unexplained bleeding or bruising, usually in later stages of illness

What if one blood sample could detect symptoms of multiple cancers at once, while also disclosing which organ may be affected? A new study from UCLA has brought that possibility a step closer to reality.

Researchers have at UCLA have developed a blood test called MethylScan that can detect molecular signals linked to multiple cancers and other diseases by analysing DNA fragments circulating in the bloodstream.

The findings, published in the Proceedings of the National Academy of Sciences, suggest the test could offer a simpler and potentially cheaper way to screen for serious diseases like cancer before their symptoms appear.

How Can One Blood Test Detect Different Cancers?

A blood test may be able to detect multiple cancers at once due to cell-free DNA (cfDNA). Every day, billions of cells die and release tiny fragments of DNA into the bloodstream. These fragments carry information about where they came from and what is happening in that tissue.

Instead of primarily searching for cancer-causing mutations, MethylScan looks at DNA methylation, a type of chemical tags that regulate how genes behave.

Different organs have distinct methylation patterns, and those patterns can change when cells become cancerous or diseased.

“DNA methylation reflects the health status of a tissue. It’s a very informative signal,” said Dr Wenyuan Li, professor of pathology and laboratory medicine at UCLA.

The researchers also developed a method to filter out the DNA released by normal blood cells, reducing the "background noise” that can make early cancer signals difficult to detect.

Also read: Studying Live Cancer Cells Could Transform Drug Discovery; Researchers Turn Cell Biology Into ‘Live Cinema’

What Are The Study's Findings?

The researchers tested MethylScan using blood samples from 1,061 people, including patients with liver, lung, ovarian and stomach cancers, people with liver diseases and healthy participants.

At 98% specificity, the test detected about 63% of cancers across all stages. For early-stage cancers, its sensitivity was around 55%.

The test also showed promise in identifying where an abnormal signal originated. This could help as a positive blood test would still need to be followed by imaging or other diagnostic tests.

“Being able to trace signals back to their source is important because a positive blood test needs to be followed by imaging or other diagnostic procedures directed at the right organ,” Li said.

Also read: Tudriqev: US FDA Approves Replimune's Skin Cancer Drug After Rejecting It Twice

Early Cancer Detection Is Key

“Early detection is crucial,” said Dr Jasmine Zhou, the study’s senior author. “Survival rates are far higher when cancers are caught before they spread.”

The findings are promising, but larger trials will be needed to establish whether such tests can reliably detect cancers in people who have no symptoms.

Also read: Following A Western Diet? Changes In Your Gut Bacteria Could Increase Colon Cancer Risk

More Developments In The Field

The findings come as another multi-cancer test, Galleri, is designed to detect signals from more than 50 cancers from a single blood sample.

Reuters reported this month that the US FDA plans to convene an advisory panel in September to review its application for approval.

But experts continue to stress that these tests are not replacements for established screening, such as mammograms or colonoscopies.